Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New York Exchange Gives Lannett Six Months To Meet Standards

Lannett ‘Evaluating All Available Options To Regain Compliance’

Executive Summary

US-based manufacturer Lannett has received a notice of non-compliance from the NYSE due to price of the company’s share. Lannett insists there is no immediate impact, but the firm is evaluating options, including “transactions that are subject to approval of Lannett’s stockholders.”

You may also be interested in...

What’s Next? Five Things To Look Out For In June

In June, Medicines for Europe will host its annual and legal affairs conferences in Barcelona, while on the commercial side Hikma’s CEO Siggi Olafsson is to resign from the London-listed company.

Lannett Kicks Off Insulin Glargine Trial

Lannett has delivered on its promise of kicking off a pivotal clinical trial for its proposed interchangeable biosimilar rival to Lantus by the end of March, as it eyes a 2023 filing and 2024 launch in the US for the insulin glargine product on which it has partnered with HEC.

Lannett: Pricing Pressure Has ‘Intensified Beyond Historical Norms’

Not many firms report a negative EBITDA when adjusted for costs, but this was the fate of Lannett during its financial Q2. Management addressed the challenges for Lannett’s base business and the ways in which the firm intends to turn the tide in the coming years.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts